- Abstract Submission Deadline: September 08, 2026
- Mid Term Registration Ends: September 10, 2026
Transforming your ideas into digital reality
Sed ut perspiciatis unde omnis natus error voluptatem santium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab nllo inventore veritatis quasi architecto beatae vitae
- Call Now
- Send Email
-
Address
8105 Rasor Blvd, Suite 112, Plano, TX 75024, USA
Abstract Submission
| TOPICS |
| Cancer Progression and Prognosis |
| Cancer Metastasis |
| Cancer Resistance |
| Cancer Microenvironment |
| The Microbiome and Cancer |
| Novel Approaches to Detect Cancer Early |
| Cancer Genetics and Biomarkers |
| Precision Oncology |
| Computational Biology and AI in Cancer |
| Therapeutic Development |
| Cancer Vaccines |
| Cancer Immunotherapies: Monotherapy and Combinations |
| Cellular Therapies for Cancer |
| Cancer Radiation Therapy |
| Targeted Therapy |
| Novel Drug Development in Cancer |
| Advances in Organ Specific Cancer Research |
| Breast Cancer |
| Brain Tumors |
| Gastrointestinal Malignancies |
| Non–Small Cell Lung Cancer |
| Ovarian Cancer |
| Sarcoma Biology |
| Neuroendocrine Cancer |
Encore Abstract Acceptance Guidelines
Encore abstracts may be considered for presentation provided that the submitting authors comply with the conference requirements and meet the following criteria:
01
Prior Presentation
The abstract or substantially similar findings may have been previously presented at another scientific meeting. Authors must disclose the prior presentation, including the conference name, date/year, and abstract or presentation number, if applicable.
02
Additional Scientific Value
Encore submissions should include substantial additional data, analyses, follow-up, or scientific interpretation that provides meaningful value beyond the original presentation, where applicable.
03
Avoidance of Duplicate Presentation
Encore abstracts should not simply reproduce the same findings for essentially the same audience. Consideration will be given to whether the new meeting provides a substantially different geographic, professional, or scientific audience.
04
Disclosure of Encore Status
Authors must clearly identify the submission as an encore presentation during the abstract submission process. If accepted, the prior presentation should also be appropriately acknowledged in the presentation materials.
05
Copyright and Publication Rights
Authors are responsible for ensuring that the submission and reproduction of previously presented or published material comply with applicable copyright, publication, and conference policies. Where necessary, permission must be obtained from the relevant copyright holder or publisher.
06
Substantial Modification
If additional data or analyses substantially change the research question, methodology, results, or conclusions, the abstract may be considered a new/original abstract rather than an encore abstract.
07
Scientific Integrity
Encore submissions must meet the same standards for scientific quality, accuracy, transparency, authorship, and ethical conduct as all other abstract submissions.
08
Conference Discretion
Acceptance of an encore abstract is at the discretion of the Scientific/Organizing Committee, which may request clarification regarding the original presentation, additional data, or the rationale for the encore submission.